Andrzej Mital
Overview
Explore the profile of Andrzej Mital including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
353
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brown J, Eichhorst B, Lamanna N, OBrien S, Tam C, Qiu L, et al.
Blood
. 2024 Sep;
144(26):2706-2717.
PMID: 39316666
The ALPINE trial established the superiority of zanubrutinib over ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma; here, we present data from the final comparative analysis...
2.
Brown J, Eichhorst B, Hillmen P, Jurczak W, Kazmierczak M, Lamanna N, et al.
Future Oncol
. 2023 Dec;
20(12):717-726.
PMID: 38088119
What Is This Summary About?: This is a plain language summary of a research study called ALPINE. The study involved people who had been diagnosed with, and previously treated at...
3.
Brown J, Eichhorst B, Hillmen P, Jurczak W, Kazmierczak M, Lamanna N, et al.
N Engl J Med
. 2022 Dec;
388(4):319-332.
PMID: 36511784
Background: In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater specificity, as treatment for relapsed or...
4.
Hillmen P, Eichhorst B, Brown J, Lamanna N, OBrien S, Tam C, et al.
J Clin Oncol
. 2022 Nov;
41(5):1035-1045.
PMID: 36395435
Purpose: Zanubrutinib is a potent, irreversible next-generation Bruton tyrosine kinase (BTK) inhibitor designed to maximize BTK occupancy and minimize off-target kinase inhibition. We hypothesized that complete/sustained BTK occupancy may improve...
5.
Kennedy V, Perkins C, Reiter A, Jawhar M, Lubke J, Kluin-Nelemans H, et al.
Blood Adv
. 2022 Sep;
7(9):1713-1724.
PMID: 36094848
Mast cell leukemia (MCL) is a rare subtype of systemic mastocytosis defined by ≥20% mast cells (MC) on a bone marrow aspirate. We evaluated 92 patients with MCL from the...
6.
Mahlangu J, Luis Lamas J, Cristobal Morales J, Malan D, Salek S, Wang M, et al.
Br J Haematol
. 2022 Aug;
200(2):229-239.
PMID: 35999026
A phase 1b/2, three-month study of marstacimab, a human monoclonal antibody targeting tissue factor pathway inhibitor (TFPI), was conducted in participants with haemophilia A or B, with or without inhibitors....
7.
Wilczynski B, Juszczyk D, Zorena K, Mital A
Physiother Theory Pract
. 2022 Apr;
39(11):2470-2478.
PMID: 35473454
Background: Currently, patients with hemophilia and inhibitor are being offered therapy, including a tissue factor pathway inhibitor (TFPI). The new prophylactic drug treatment may allow for new opportunities for other...
8.
Gotlib J, Reiter A, Radia D, Deininger M, George T, Panse J, et al.
Nat Med
. 2021 Dec;
27(12):2192-2199.
PMID: 34873345
Advanced systemic mastocytosis (AdvSM) is a rare, KIT D816V-driven hematologic neoplasm characterized by mast cell infiltration and shortened survival. We report the results of a prespecified interim analysis of an...
9.
Szudy-Szczyrek A, Bachanek-Mitura O, Gromek T, Chromik K, Mital A, Szczyrek M, et al.
J Clin Med
. 2021 Apr;
10(5).
PMID: 33799933
In April 2017 midostaurin was approved by the US Food and Drug Administration for the treatment of patients with aggressive systemic mastocytosis (ASM). So far, very limited real world data...
10.
Lopatniuk P, Puchalska Z, Mital A, Mikosik A, Frackowiak J, Hellmann A, et al.
Acta Biochim Pol
. 2020 Jun;
67(2):247-257.
PMID: 32544313
B-cell Chronic Lymphocytic Leukemia (B-CLL) is the most common hematological disorder among middle-aged/elderly people in the Western countries. We have shown earlier that B-CLL cells exhibit elevated total amount and...